“It’s never too late to retire early”
Despite the pandemic and a worldwide economic recession, U.S. stocks turned a banner year in 2020. The U.S. Food and Drug Administration approved an astounding 53 novel drugs last year. This is a considerable amount of money flowed into pharmaceutical research. While many high-dollar business deals were consummated across the industry. However, several of these critical tailwinds are unlikely to roll over into 2021.
Biopharma investors may want to scale back on speculative growth stocks in the industry. It would be wise to focus on value-oriented investments. Companies with attractive price-to-earnings ratios, strong free cash flows, and healthy dividends are smart bets in uncertain times, after all.
Do not miss this big trade reveal
Paul Mampilly is a Wall Street legend.
(Barron’s crowned his hedge fund as the “world’s best” and Kiplinger ranked it in the top 1%.)
But a few years ago, he left Wall Street.
“I just grew tired of helping the rich get richer,” Paul explains. “So I started sharing my No. 1 investment picks with Main Street Americans.”And his No. 1 stock picks have been phenomenal.
In 2016, Paul’s No. 1 pick — Tableau Software — shot up 199%.
In 2017, Paul’s No. 1 pick — Foundation Medicine — shot up 524%.
In 2018, Paul’s No. 1 pick — Roku — shot up 393%.
In 2019, Paul’s No. 1 pick — MTech Acquisitions — shot up 332%.
But Paul believes his No. 1 stock pick for 2021 could go even higher. (By clicking this link you will be automatically opted into Bold Profits Daily)
Headlines you shouldn’t miss
It’s never too late to start saving,
Know someone who’d love the Never Too Late Investor? Be sure to send them to this link so they can get signed up: investinglate.com